Logo Lanfrica

Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)

Domaine:

healthcare
Créateur:
Gla
Éditeur:
Viv
Hôte:avatar
This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection, when administered as a primary vaccination integrated into an Expanded Program on Immunization (EPI) regimen to infants living in sub-Saharan Africa.

Tags

Conditions: MalariaInterventions: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049Interventions: Engerix-B™ vaccineInterventions: Infanrix/Hib™ vaccineInterventions: Polio Sabin™ vaccineInterventions: Rotarix™ vaccineInterventions: Synflorix™ vaccineInterventions: Measles vaccineInterventions: Yellow fever vaccine

Licenses

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Similaires

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity infor

OC 8546 SAFETY AND IMMUNOGENICITY OF THE MALARIA VACCINE CANDIDATE BK-SE36 IN YOUNG CHILDREN LIVING IN BURKINA FASO

Background The malaria blood stage vaccine candidate SE-36 is based on the serin

Association of hepatitis B surface antigen carriage with severe malaria in Gambian children.

Severe malaria is a major cause of childhood mortality in sub-Saharan Africa but the factors predisp

Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations

The interaction of multiple viruses in one host is thought to enhance the development of mutations.

Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2

Abstract Background GMZ2 is a recomb